MEDLINE Journals

    Use of specialty care versus standard retail pharmacies for treatment of hepatitis C.

    Authors
    Cohen SM, Kwasny MJ, Ahn J 
    Source
    Ann Pharmacother 2009 Feb; 43(2) :202-9.
    Abstract

    Treatment for hepatitis C virus (HCV) is associated with significant adverse events. Improved adherence increases the probability of achieving sustained virologic response (SVR). Despite a lack of supporting literature, the use of specialty care pharmacies has increased in recent years in an attempt to improve HCV treatment outcomes.To compare specialty care versus standard retail pharmacies in HCV treatment outcomes, utilization of office resources, and the use of supplemental medications.A retrospective chart review was performed at a single academic institution for adults with HCV infection treated between 2001 and 2006. SVR was the primary endpoint. Secondary endpoints included therapy completion rates, HCV treatment dose reductions, additional phone calls and clinic visits, and the use of supplemental medications.One hundred ninety-seven patients were identified (102 standard and 95 specialty care pharmacy). There were no differences in baseline demographics between the groups, except for a higher proportion of African Americans using specialty care pharmacies. Overall SVR was 103/197 (52%). SVR was 57/102 (56%) in the standard pharmacy group and 46/95 (48%) in the specialty care pharmacy group. There were no statistically significant differences with regard to SVR (even after accounting for differences in ethnicity), the use of supplemental medications, additional clinic phone calls and visits required, and the reasons for HCV therapy discontinuation. There was a statistically significantly higher incidence of HCV medication dose reductions in the standard retail pharmacy group (45% vs 28%; p = 0.016).The use of specialty care pharmacies for the treatment of HCV was not associated with higher SVR rates. Patients using specialty care pharmacies had a lower incidence of interferon and/or ribavirin dose reductions, but there was no difference between the groups in therapy completion rates, use of additional office resources, or use of supplemental medications.

    Mesh
    Antiviral Agents
    Community Pharmacy Services
    Ethnic Groups
    Female
    Genotype
    Hepatitis C
    Humans
    Infectious Disease Medicine
    Male
    Medication Adherence
    Middle Aged
    Treatment Outcome
    Language

    eng

    Pub Type(s)
    Comparative Study Journal Article
    PubMed ID

    19193591

    Content Manager
    Related Content

    Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.

    Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.

    Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

    Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.

    Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.

    Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy.

    The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.

    Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.